Acute Biliary Pancreatitis - Optimal Time for Cholecystectomy

September 4, 2018 updated by: Mohammed Ahmed Omar, South Valley University

Acute Biliary Pancreatitis - Optimal Time for Cholecystectomy: A Prospective Randomized Study

In patients with mild gallstone pancreatitis, early cholecystectomy within 48 hours might reduce the risk of recurrent gallstone-related complications, compared with the more commonly used strategy in our locality of conservative management and delayed cholecystectomy. However, evidence to support early cholecystectomy is poor, and concerns exist about an increased risk of cholecystectomy-related complications with this approach. In this study, we aimed to compare the benefits and harms of early versus delayed cholecystectomy in patients with mild biliary pancreatitis.

Study Overview

Detailed Description

Inclusion criteria

  1. Patient diagnosed with a first attack of mild biliary pancreatitis
  2. Age ≥ 18 years
  3. American Society of Anesthesiologists (ASA) grade I, II or III
  4. a serum C-reactive protein (CRP) concentration less than 100 mg/L,
  5. no need for opioid analgesics,
  6. normal oral diet tolerance Exclusion criteria

1. chronic pancreatitis 2. alcohol abuse 3. pregnancy The number of patients needed was calculated. Considering a power of 80% and reliability of 0.05, we found that 53 patients should be present in each group. Eligible patients will be randomly divided into two equal groups (Group 1: early cholecystectomy, Group 2: delayed cholecystectomy) according to a computer-generated random numbers.

Procedure Early cholecystectomy was done within 48 after admission. Delayed cholecystectomy was done after 30 days after randomization. All cholecystectomies were done by, or under the direct supervision of, a surgeon who had undertaken at least 100 cholecystectomies in the past 5 years.

Study Type

Interventional

Enrollment (Actual)

2

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patient diagnosed with a first attack of mild biliary pancreatitis
  2. Age ≥ 18 years
  3. American Society of Anesthesiologists (ASA) grade I, II or III
  4. a serum C-reactive protein (CRP) concentration less than 100 mg/L,
  5. no need for opioid analgesics,
  6. normal oral diet tolerance

Exclusion Criteria:

  • 1. chronic pancreatitis 2. alcohol abuse 3. pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: early cholecystectomy
Early cholecystectomy was done within 48 after admission
cholecystectomy was done within 48 after admission
SHAM_COMPARATOR: delayed cholecystectomy
Delayed cholecystectomy was done after 30 days after randomization.
cholecystectomy was done after 30 days after randomization

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gallstone related complications
Time Frame: 6 month of onset of pancreatitis
recurrent pancreatitis, cholecystitis, cholangitis, obstructive choledocholithiasis needing endoscopic retrograde cholangiopancreatography, or gallstone colic
6 month of onset of pancreatitis

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difficulty of cholecystectomy
Time Frame: up to 3 hours
the degree of difficulty of the procedureas assessed by the most experienced surgeon on a 0-10 visual analogue scale
up to 3 hours
Conversion to open cholecystectomy
Time Frame: up to 2 hours
up to 2 hours
Operative time
Time Frame: up to 10 hours
from the begging of the operation to recovery of patient
up to 10 hours
Cholecystectomy related complications
Time Frame: up to 1 month
up to 1 month
additional surgical, endoscopic, or radiological intervention
Time Frame: up to 6 month
up to 6 month
Gall stones non related complications
Time Frame: up to 6 month
up to 6 month
Length of hospital stay of index admission
Time Frame: from admission to discharge of patient, up to 10 days
from admission to discharge of patient, up to 10 days
Number of readmission
Time Frame: up to 6 month
up to 6 month
Total length of hospital stay (including readmission)
Time Frame: up to 6 month
up to 6 month
The number of patient-reported colics irrespective of readmission
Time Frame: up to 6 month
up to 6 month
Need for intensive care unit admission
Time Frame: up to 6 month
up to 6 month
Mortality
Time Frame: up to 6 month
death from gall stone related complication
up to 6 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 1, 2014

Primary Completion (ACTUAL)

September 1, 2017

Study Completion (ACTUAL)

December 1, 2017

Study Registration Dates

First Submitted

March 19, 2017

First Submitted That Met QC Criteria

March 19, 2017

First Posted (ACTUAL)

March 21, 2017

Study Record Updates

Last Update Posted (ACTUAL)

September 6, 2018

Last Update Submitted That Met QC Criteria

September 4, 2018

Last Verified

September 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • SVU 148

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Biliary Pancreatitis

Clinical Trials on early cholecystectomy

3
Subscribe